StreetInsider.com News Articles

Sagimet Biosciences (SGMT) Reiterated at Market Outperform by Citizens

Thu, 12 Mar 2026 05:30:33 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $35.00 price target on Sagimet Biosciences Inc (NASDAQ: SGMT).

The analyst commented, "We continue to like SGMT’s position in MASH, with the denifanstat/resmetirom combo targeting F4 MASH, which is the highest unmet need. The company completed its Phase 1 PK trial of the combo, which we view as a meaningfully de-risking step. The combination is mechanistically compelling, pairing FASN inhibition with THR-beta agonism, with the company recently securing resmetirom API forms to support the development of an oral fixed-dose combination. As a reminder, in its Phase 2 trial, 11 of 13

Oppenheimer Reiterates Outperform Rating on Sagimet Biosciences Inc (SGMT) following Q4 results

Wed, 11 Mar 2026 16:04:01 -0400

Oppenheimer analyst Jay Olson reiterated an Outperform rating and $25.00 price target on Sagimet Biosciences Inc (NASDAQ: SGMT)

The analyst commented, "SGMT reported 4Q25 results with $10.8M OpEx and $113.1M cash providing expected runway into 3Q27. We see key recent progress and several upcoming catalysts, including: 1) Ph1 PK study of the denifanstat plus resmetirom combination now supports a Ph2 trial in F4 MASH patients expected to initiate in 2H26; 2) partner Ascletis recently reported positive 52-week Ph3 results for denifanstat in moderate/severe acne demonstrating efficacy with favorable safety/tolerability supporting NDA filing acceptance by the Chinese NMPA, and we expect approval

Form S-8 Sagimet Biosciences Inc.

Wed, 11 Mar 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260311/26142874.html

Form S-8 Sagimet Biosciences Inc.

Wed, 11 Mar 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260311/26142874.html

Form S-8 Sagimet Biosciences Inc.

Wed, 11 Mar 2026 07:59:00 -0400

si-local-file:///var/storage/secattach/20260311/26142737.html

Form S-8 Sagimet Biosciences Inc.

Wed, 11 Mar 2026 07:59:00 -0400

si-local-file:///var/storage/secattach/20260311/26142737.html

Form 8-K Sagimet Biosciences Inc. For: Mar 11

Wed, 11 Mar 2026 07:42:00 -0400

si-local-file:///var/storage/secattach/20260311/26142688.html

Form 8-K Sagimet Biosciences Inc. For: Mar 11

Wed, 11 Mar 2026 07:42:00 -0400

si-local-file:///var/storage/secattach/20260311/26142688.html

Form 10-K Sagimet Biosciences Inc. For: Dec 31

Wed, 11 Mar 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260311/26142647.html

Form 10-K Sagimet Biosciences Inc. For: Dec 31

Wed, 11 Mar 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260311/26142647.html

Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

Wed, 11 Mar 2026 07:30:00 -0400

Completed Phase 1 pharmacokinetic (PK) clinical trial of denifanstat and resmetirom combination

Phase 2 trial of denifanstat/resmetirom combination in F4 MASH patients planned to
initiate in 2H 2026

Secured global, exclusive license to TAPI’s innovative forms of resmetirom active pharmaceutical ingredients (API)

First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing

Positive topline results in open-label Phase 3 trial evaluating the long-term safety of denifanstat in patients with moderate to severe acne in China reported by Ascletis

Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

Wed, 11 Mar 2026 07:30:00 -0400

Completed Phase 1 pharmacokinetic (PK) clinical trial of denifanstat and resmetirom combination

Phase 2 trial of denifanstat/resmetirom combination in F4 MASH patients planned to
initiate in 2H 2026

Secured global, exclusive license to TAPI’s innovative forms of resmetirom active pharmaceutical ingredients (API)

First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing

Positive topline results in open-label Phase 3 trial evaluating the long-term safety of denifanstat in patients with moderate to severe acne in China reported by Ascletis

Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences

Wed, 25 Feb 2026 07:00:00 -0400

SAN MATEO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in three upcoming investor conferences.

TD Cowen 46th Annual Health Care Conference in Boston, MA, on March 2, 2026, with a fireside chat at 1:10pm ET (link here).
Leerink Global Healthcare Conference in Miami, FL, on March 9, 2026, with a fireside chat at 1pm ET (link here).
The Citizens Life Sciences Conference in Miami, FL, on March 10,

Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences

Wed, 25 Feb 2026 07:00:00 -0400

TD Cowen 46th Annual Health Care Conference in Boston, MA, on March 2, 2026, with a fireside chat at 1:10pm ET (link here).
Leerink Global Healthcare Conference in Miami, FL, on March 9, 2026, with a fireside chat at 1pm ET (link here).
The Citizens Life Sciences Conference in Miami, FL, on March 10,

Form 4 Sagimet Biosciences Inc. For: Feb 19 Filed by: Rozek Elizabeth

Fri, 20 Feb 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260220/26036790.html

Form 4 Sagimet Biosciences Inc. For: Feb 19 Filed by: Rozek Elizabeth

Fri, 20 Feb 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260220/26036790.html

Form 4 Sagimet Biosciences Inc. For: Feb 19 Filed by: Martins Eduardo Bruno

Fri, 20 Feb 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260220/26036776.html

Form 4 Sagimet Biosciences Inc. For: Feb 19 Filed by: Martins Eduardo Bruno

Fri, 20 Feb 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260220/26036776.html

Form 4 Sagimet Biosciences Inc. For: Feb 19 Filed by: Happel David

Fri, 20 Feb 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260220/26036752.html

Form 4 Sagimet Biosciences Inc. For: Feb 19 Filed by: Happel David

Fri, 20 Feb 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260220/26036752.html

Form 4 Sagimet Biosciences Inc. For: Feb 19 Filed by: Chauche Thierry

Fri, 20 Feb 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260220/26036728.html

Form 4 Sagimet Biosciences Inc. For: Feb 19 Filed by: Chauche Thierry

Fri, 20 Feb 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260220/26036728.html

Form 4 Sagimet Biosciences Inc. For: Feb 10 Filed by: Happel David

Thu, 12 Feb 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260212/25991885.html

Form 4 Sagimet Biosciences Inc. For: Feb 10 Filed by: Happel David

Thu, 12 Feb 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260212/25991885.html

Form 4 Sagimet Biosciences Inc. For: Feb 10 Filed by: Chauche Thierry

Thu, 12 Feb 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260212/25991815.html